Nuclear chemist working in the field of radiation biology.

I earned my MSc in Radiation Biology from the University of Oxford, followed by a PhD in Oncology at Institut Curie and the University of Paris-Saclay. Currently, I conduct research at CHUV in Lausanne, Switzerland, focusing on the clinical translation of FLASH radiotherapy through preclinical studies. My work explores the role of oxygen in the FLASH effect, the impact of temporal beam parameters, and the integration of standard-of-care approaches, particularly fractionated radiotherapy.

Dr. Verginadis is a Research Assistant Professor in the Department of Radiation Oncology at the University of Pennsylvania. He is trained as a Molecular and Radiation Biologist, with extensive experience and numerous publications in the fields of normal tissue response to radiation, development of clinically relevant mouse models for radiotherapy, FLASH proton radiotherapy, tumor microenvironment, and cancer biology.

Zach Reitman MD, PhD is Assistant Professor of Radiation Oncology, Pathology, and Neurosurgery at Duke University.  He completed an MD/PhD at Duke in 2014, and a Radiation Oncology residency and research fellowship at Harvard in 2019.  He is a physician-scientist and sees brain tumor patients in the Duke Radiation Oncology clinic.  Dr. Reitman’s research lab is funded by the NIH and brain tumor research foundations.  His research focuses on radiation biology and genetic mouse models of brain tumors, with a goal of identifying improved treatment approaches for brain tumor patients.  Dr. Reitman recently co-authored a paper in Nature Cancer with Dr. Yi Fan and other collaborators at the University of Pennsylvania linking proton FLASH-RT to improved outcomes after CAR T cell therapy in preclinical mouse models of medulloblastoma.  He is currently working with a team at Duke University leveraging a unique very high energy electron FLASH beam to examine the FLASH effect on brain tissues and brain tumor models.